1-(3-(5-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)propyl)-4-(3,4-dimethylphenyl)piperazine | 1055191-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-(5-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)propyl)-4-(3,4-dimethylphenyl)piperazine
• 英文别名: 1-(3,4-dimethylphenyl)-4-[3-[5-(4-methoxyphenyl)-1-phenylpyrazol-3-yl]propyl]piperazine
• CAS: 1055191-29-1
• 化学式: C₃₁H₃₆N₄O
• 分子量: 480.653
• InChiKey: PKIMOEPBOYURCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  33.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(5-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)propanal 、 1-(3,4-二甲基苯基)哌嗪 在 NaBH(OAc)3 、 N,N-二异丙基乙胺 作用下， 生成 1-(3-(5-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)propyl)-4-(3,4-dimethylphenyl)piperazine
  参考文献：
  名称：

  PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

  摘要：

  本发明涉及一种新的哌嗪基丙基吡唑衍生物，以及其制备方法和含有该衍生物的药用组合物。本发明的新哌嗪基丙基吡唑衍生物具有对多巴胺D4受体的优越选择性亲和力，可以有效抑制阿波吗啡诱导的精神病行为（笼子攀爬），并在小鼠转杆试验中具有相对较低的不良影响。因此，它可以作为治疗和预防中枢神经系统（CNS）疾病的治疗剂，特别是精神分裂症、注意力缺陷多动障碍、抑郁症、压力疾病、恐慌症、恐惧症、强迫症、创伤后应激障碍、认知障碍、阿尔茨海默病、帕金森病、焦虑症、偏执狂、狂躁症、癫痫障碍、人格障碍、偏头痛、药物成瘾、酒精成瘾、肥胖症、进食障碍和睡眠障碍的治疗剂进行开发。

  公开号：

  US20100063286A1

文献信息

• Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same
  申请人：Korea Research Institute of Chemical Technology

  公开号：US08236806B2

  公开（公告）日：2012-08-07

  The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.

  本发明涉及一种新型哌嗪基丙基吡唑衍生物、其制备方法以及包含该衍生物的药学上可接受的组合物。本发明的新型哌嗪基丙基吡唑衍生物具有对多巴胺D4受体的优异选择性亲和力，能够有效抑制阿泼吗啡引起的精神病行为（笼子攀爬），并在小鼠转杆试验中具有相对较低的不良反应。因此，它可以作为治疗和预防中枢神经系统（CNS）疾病的治疗剂，特别是精神分裂症、注意力缺陷多动障碍、抑郁症、压力疾病、惊恐障碍、恐惧症、强迫症、创伤后应激障碍、认知障碍、阿尔茨海默病、帕金森病、焦虑症、妄想症、躁狂症、癫痫、人格障碍、偏头痛、药物成瘾、酒精成瘾、肥胖症、进食障碍和睡眠障碍的治疗剂开发。
• US8236806B2
  申请人：——

  公开号：US8236806B2

  公开（公告）日：2012-08-07
• US8372844B2
  申请人：——

  公开号：US8372844B2

  公开（公告）日：2013-02-12
• [EN] PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME<br/>[FR] DÉRIVÉS PIPÉRAZINYL-PROPYL-PYRAZOLE SERVANT D'ANTAGONISTES AUX RÉCEPTEURS DOPAMINERGIQUES D4, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：KOREA RES INST CHEM TECH

  公开号：WO2008108517A2

  公开（公告）日：2008-09-12

  [EN] The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.
  [FR] L'invention concerne un nouveau dérivé pipérazinyl-propyl-pyrazole, et une méthode permettant de le préparer, ainsi qu'une composition pharmaceutiquement acceptable contenant ce dérivé. Le nouveau dérivé pipérazinyl-propyl-pyrazole de l'invention présente une affinité sélective supérieure pour le récepteur dopaminergique D4, il peut inhiber de manière efficace un comportement psychotique (consistant à grimper sur la paroi de la cage) induit par de l'apomorphine et présente des effets nuisibles relativement faibles lors d'un test de la tige tournante subi par des souris. Ainsi, le dérivé de l'invention peut être développé pour servir d'agent thérapeutique destiné au traitement et à la prévention de troubles du système nerveux central, en particulier: la schizophrénie, un ehyperactivité associée à une déficience d'attention, la dépression, des maladies liées au stress, des crises de panique, une phobie, un trouble obsessionnel compulsif, un trouble de stress post-traumatique, un trouble cognitif, la maladie d'Alzheimer, la maladie de Parkinson, l'anxiété, la paraphrénie, la manie, des troubles convulsifs, des troubles de la personnalité, la migraine, la dépendance à la drogue, la dépendance à l'alcool, l'obésité, des troubles alimentaires et des troubles du sommeil.
• PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Kong Jae Yang

  公开号：US20100063286A1

  公开（公告）日：2010-03-11

  The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.

  本发明涉及一种新的哌嗪基丙基吡唑衍生物，以及其制备方法和含有该衍生物的药用组合物。本发明的新哌嗪基丙基吡唑衍生物具有对多巴胺D4受体的优越选择性亲和力，可以有效抑制阿波吗啡诱导的精神病行为（笼子攀爬），并在小鼠转杆试验中具有相对较低的不良影响。因此，它可以作为治疗和预防中枢神经系统（CNS）疾病的治疗剂，特别是精神分裂症、注意力缺陷多动障碍、抑郁症、压力疾病、恐慌症、恐惧症、强迫症、创伤后应激障碍、认知障碍、阿尔茨海默病、帕金森病、焦虑症、偏执狂、狂躁症、癫痫障碍、人格障碍、偏头痛、药物成瘾、酒精成瘾、肥胖症、进食障碍和睡眠障碍的治疗剂进行开发。